TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Characterizing the Effects of Family History of Alcoholism on Alcohol Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Consume at least 1 drink/month over the past 6 months~Exclusion Criteria:~* History of chronic pain~* Current use of opioids~* Current major depression~* History of any psychotic disorder~* Undercontrolled hypertension or diabetes~* History of neurologic disease~* History of serious medical illness~* History of drug or alcohol dependence, including nicotine, or a pattern of hazardous alcohol use~* Safety concerns related to MRI (for example, implants or pacing devices)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Family History Positive (Type: EXPERIMENTAL): People reporting at least one parent with a history of alcohol problems.
- Family History Negative (Type: EXPERIMENTAL): People who do not report having a parent with a history of alcohol problems.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, ≥ 18 years old.~2. Diagnosed with COVID-19, as evaluated by PCR test confirming infection with SARS-CoV-2, or suspected COVID-19 diagnosis based on radiological clinical findings.~3. Respiratory distress as evidenced by at least two of the following:~   * Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.)~  * Recording of SpO2 ≤ 90% or the patient is requiring supplemental oxygen to maintain an SpO2 ≥ 90%~  * Requiring supplemental oxygen~  * Diagnosis of mild, moderate, or severe ARDS by Berlin definition~4. A signed informed consent form from the patient or the patient's legal representative must be available.~Exclusion Criteria:~1. In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.~2. Patient has a do-not-resuscitate (DNR) or do-not-intubate (DNI) order in place~3. Patient has severe chronic obstructive pulmonary disease (COPD), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.).~4. Patient is on chronic immunosuppressive medication.~5. As a result of the medical review and screening investigation, the Principal Investigator considers the patient unfit for the study.~6. A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate).~7. Patient has known pregnancy or is currently breastfeeding.~8. Participation in another clinical trial (not including treatments for COVID-19 as approved by the FDA through expanded access or compassionate use).~9. Baseline QT prolongation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ampion (Type: EXPERIMENTAL): Ampion
- Standard of Care (Type: OTHER): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnostic report had to include evidence for morphological and cyclin D1 or t (11; 14).~2. Eastern Cooperative Oncology Group performance status of 0-2.~3. Measurable disease by computed tomography/magnetic resonance imaging.~4. Received prior regimens for MCL.~5. Documented failure to achieve any response, (stable disease or progressive disease during treatment) or documented progressive disease after response to the most recent treatment regimen.~6. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN).~7. Total bilirubin ≤ 2 x ULN (unless documented Gilbert's syndrome).~8. Life expectancy of \> 4 months.~Key Exclusion Criteria:~1. Current or history of central nervous system lymphoma.~2. Prior exposure to a BTK inhibitor before enrollment.~3. Prior corticosteroids with anti-neoplastic intent within 7 days.~4. Major surgery within 4 weeks of screening.~5. Toxicity must have recovered from prior chemotherapy.~6. History of other active malignancies within 2 years of study entry.~7. Currently clinically significant active cardiovascular disease.~8. QT interval corrected with Fridericia's formula \> 450 microseconds or other significant electrocardiogram abnormalities.~9. Uncontrolled systemic infection or infection requiring parenteral anti-microbial therapy.~10. Known human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection (detected positive by polymerase chain reaction).~Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Zanubrutinib (Type: EXPERIMENTAL): Zanubrutinib (160 milligrams) administered orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have suboptimal glycaemic control as evidenced by an HbA1c 7.1% to 10.0%, inclusive~* Have a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive~* Are receiving metformin at a stable dose (consistent with country specific requirements) of a minimum of 1000mg for at least 3 months prior to start start OR are receiving metformin at a minimum dose (consistent with country specific requirements) of 1000mg and sulphonylurea (as separate medications not as a fixed dose combination) at stable doses for 3 months prior to study start~Exclusion Criteria:~* Have any contraindication for the OAD that they have been using~* Have a known allergy or hypersensitivity to insulin detemir, exenatide or excipients contained in these agents~* Have been treated within 4 weeks of screening with systemic glucocorticoid therapy by oral, intravenous (IV) or intramuscular (IM) route, or are regularly treated with potent, inhaled intranasal steroids that are known to have a high rate of systemic absorption. Exceptions to this criterion include patients who are receiving glucocorticoid therapy for corticotropic hypopituitary deficiency (e.g. Addison disease)~* Have been treated with drugs that promote weight loss, within 3 months of screening~* Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to screening: insulin, alpha-glucosidase, Byetta® (exenatide BID formulation), thiazolidinediones (TZD), dipeptidyl peptidase (DPP)-4 inhibitors~* Have previously completed or withdrawn from this study or any other study investigating exenatide QW~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry~* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with chronic hepatitis C virus (HCV) genotype 1, 2, 4, 5 or 6 infection~* Documented as treatment naive or experienced with a prior regimen consisting of Interferon (IFN) +/-Ribavirin (RBV) regimen without achieving sustained viral response~* Absence of cirrhosis~* Screening laboratory values within defined thresholds~* Must use specific contraceptive methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV)~* Prior exposure to an HCV direct-acting antiviral agent (DAA), either in combination with pegylated interferon (PegIFN) or IFN-free~* Current or prior history of clinical hepatic decompensation~* History of clinically significant illness or any other medical disorder including cardiovascular conditions that may interfere with individual's treatment, assessment or compliance with the protocol~* Pregnant or a nursing female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
- Group B (Type: EXPERIMENTAL): AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 years or above~* Patients scheduled for elective total hip replacement~Exclusion Criteria:~* Planned, staged total bilateral hip replacement~* Active bleeding or high risk of bleeding contraindicating treatment with low molecular weight heparin~* Contraindication listed in the labeling or conditions precluding patient treatment with enoxaparin~* Conditions prohibiting bilateral venography (e.g. amputation of one leg, allergy to contrast media)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~All Participants:~-Judged to be in good physical health on the basis of medical history, physical examination and laboratory results~Boys and Girls 9 to 14 Years:~-Must not have had coitarche and does not plan on becoming sexually active during the vaccination period~Women 16 to 26 Years:~* Has never had a Papanicolaou (Pap) test or only had normal Pap test results~* A lifetime history of 0 to 4 male and/or female sexual partners~Exclusion Criteria:~All Participants:~* Known allergy to any vaccine component~* History of severe allergic reaction that required medical intervention~* Thrombocytopenia or any coagulation disorder~* Females only: participant is pregnant or expecting to donate eggs during day 1 through month 7~* Currently immunocompromised, or been diagnosed with immunodeficiency~* Had a splenectomy~* Receiving or has received immunosuppressive therapies within the last year~* Received any immunoglobulin product or blood-derived product within 3 months~* Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- Girls 9 to 14 Years V503 at Months 0 and 6 (Type: EXPERIMENTAL): Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
- Boys 9 to 14 Years V503 at Months 0 and 6 (Type: EXPERIMENTAL): Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
- Girls and Boys 9 to 14 Years V503 at Months 0 and 12 (Type: EXPERIMENTAL): Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
- Girls 9 to 14 Years V503 at Months 0, 2, and 6 (Type: EXPERIMENTAL): Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
- Young Women 16 to 26 Years V503 at Months 0, 2, and 6 (Type: ACTIVE_COMPARATOR): Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Compare 3 Multi-Layered Foam Dressings for the Management of Chronic Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects 18-85 years of age with leg and foot ulcers (i.e. VLU, DFU).~2. Signed informed consent.~3. Subject and/or caregiver must be willing and able to tolerate multi-layered compression bandages when applicable and offloading footwear.~4. Study subject must be available and able to visit the clinic weekly for the full 4-week period.~Exclusion Criteria:~1. Pressure ulcers should not be included. Pressure injury as defined by the National Pressure Ulcer Advisory Panel (NPUAP).~2. Presence of local wound infection as determined by study doctor based on clinical signs and symptoms.~3. Subject has any evidence of peripheral arterial disease (PAD).~4. Subject diagnosed with malignancy other than cutaneous basal cell carcinoma.~5. Subject has received growth factor therapy (e.g. autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix e.g. amnion, amniotic tissue) within 2 weeks of screening date.~6. Pregnancy or lactation at time of study participation.~7. Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization.~8. Subject is currently enrolled or participated in another investigational device, drug or biological trial within 30 days of baseline of this study.~9. Present history of alcohol or drug abuse.~10. Known allergy/hypersensitivity to any of the components of the dressing.~11. Subject not suitable for the investigation according to the investigator's judgment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Five-layer vs Hydropolymer (Type: ACTIVE_COMPARATOR): Bordered Five-layer Foam Dressing for 2 weeks, followed by Hydropolymer Foam Dressing for 2 weeks.
- Hydropolymer vs Five-layer (Type: ACTIVE_COMPARATOR): Hydropolymer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
- Five-layer vs Hydrocellular (Type: ACTIVE_COMPARATOR): Bordered Five-layer Foam Dressing for 2 weeks, followed by Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks.
- Hydrocellular vs Five-layer (Type: ACTIVE_COMPARATOR): Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Highdose Nicotine Patch Therapy for Smokeless Tobacco Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. are at least 18 years of age and at most 55 years of age;~2. report daily ST use for the past 12 months;~3. identify ST as their primary tobacco product;~4. use an average of ≥ 3 cans/pouches per week;~5. are in general good health (determined by medical history and screening physical examination);~6. have been provided with, understand, and have signed the informed consent.~Exclusion Criteria:~1. are currently using (past 30 days) any other behavioral or pharmacologic tobacco treatment program;~2. are currently pregnant or lactating;~3. have had unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months;~4. have a history of arrhythmia or an abnormal tracing on the baseline EKG;~5. have a blood pressure of greater than 140/90 or a pulse of more than 110 beats per minute;~6. have a history of severe skin allergies or dermatoses;~7. have a history of intolerance to nicotine patches;~8. have another member of their household already participating in this study;~9. are taking a medication known to interact with nicotine (i.e., clozapine);~10. are taking any prescription medication for depression or asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): 2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
- placebo (Type: PLACEBO_COMPARATOR): 2 patches (containing non active ingredients) per day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Osteoarthritis Topical Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male or female patients aged at least 40 years.~* Primary osteoarthritis in a single knee joint, grade II/III based on the Kellgren and Lawrence classification system.~* Radiographic evidence consistent with osteoarthritis carried out within 6 months before screening.~* pain is currently not adequately controlled with a simple analgesic or an NSAID OR would necessitate treatment, but is not yet treated.~Main Exclusion Criteria:~* Concomitant presence of another type of continuous pain that is more severe in intensity in comparison with the osteoarthritis target joint pain~* Osteoarthritis causing significant pain in any joint other than the identified knee, or contralateral knee (≥ 20 mm pain) as confirmed by a separate VAS at visit 1 for any other painful joint concerned.~* Female patients who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibuprofen (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1 -Age older than 18 years of both male and female genders. 2-Individuals diagnosed with PD based on the presence of 2 of 3 cardinal features \& UK bank criteria for idiopathic Parkinson's disease. 3-Patients with motor complications of PD (Hoehn and Yahr stage 2-3)(on therapy) and at least 2 hours off time.~Exclusion Criteria:~1 -Patients with atypical or secondary Parkinsonism syndromes excluding PD. 2-Patients who could not perform the tests. 3-Women who were or might be pregnant, who did not practice effective contraception and were of childbearing potential, or who were breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients 25 ZNS (Type: ACTIVE_COMPARATOR): 30 patients receive oral 25 mg ZNS daily
- Patients 50 ZNS (Type: ACTIVE_COMPARATOR): 30 patients receive oral 50 mg ZNS daily
- Patients Placebo (Type: PLACEBO_COMPARATOR): 30 patients receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete